The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies

Central Nervous System Agents in Medicinal Chemistry

Volumn 10, Issue 1, 2010, Pages 47-64

  Rivers, Jack Rocky Jay ^a   Ashton, John Clive ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cannabinoid; CBII receptor; Microglia; Neurodegeneration; Neuroinflammation

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 1,8 NAPHTHYRIDIN 4(1H) ON 3 CARBOXAMIDE; 2 IMINO 1,3 THIAZOLIDINE DERIVATIVE; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ALKOXYARYLBENZIMIDAZOLECARBOXAMIDE DERIVATIVE; AMIDE; ANANDAMIDE; CANNABINOID; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR AGONIST; DRONABINOL; INDOLE DERIVATIVE; JWH 139; JWH 142; JWH 143; JWH 229; MINOCYCLINE; N ALKYLAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; O 1191; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLIN 4(1H) ON 3 CARBOXAMIDE DERIVATIVE; RIMONABANT; TETRAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BRAIN HYPOXIA; BRAIN INJURY; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; COMPUTER MODEL; DEGENERATIVE DISEASE; DOWN SYNDROME; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; MAJOR DEPRESSION; MICROGLIA; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEUROPATHOLOGY; NEUROPATHY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; STROKE; STRUCTURE ACTIVITY RELATION; SUBVENTRICULAR ZONE;

EID: 77951100273     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152410790780145     Document Type: Review

References (224)

1. Bouaboula, M.; Poinot-Chazel, C.; Marchand, J.; Canat, X.; Bourrie, B.; Rinaldi Carmona, M.; Calandra, B.; LeFur, G.; Casellas, P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor - Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem., 1996, 237 (3), 704-711. (Pubitemid 126443878)
2. Gilman, A.G.; Hardmand, J.G.; Limbird, L.E. Eds. The Pharmacological Basis of Therapeutics; McGraw-Hill: New York, 2001.
3. Facchinetti, F.; Del Giudice, E.; Furegato, S.; Passarotto, M.; Leon, A. Cannabinoids ablate release of TNF alpha in rat microglial cells stimulated with lypopolysaccharide. Glia, 2003, 41 (2), 161-168. (Pubitemid 36262193)
4. Ashton, J.C.; Glass, M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharm., 2007, 5 (2), 73-80. (Pubitemid 47019422)
5. Benito, C.; Tolon, R.M.; Pazos, M.R.; Nunez, E.; Castillo, A.I.; Romero, J. Cannabinoid CB2 receptors in human brain inflammation. Br. J. Pharmacol., 2008, 153 (2), 277-285.
6. Ashton, J.C.; Rahman, R.M.; Nair, S.M.; Sutherland, B.A.; Glass, M.; Appleton, I. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci. Lett., 2007, 412 (2), 222-226.
7. Fernandez-Ruiz, J.; Romero, J.; Valesco, G.; Tolon, R.M.; Ramos, J.A.; Guzman, M. Cannabinoid CB2 receptor: a new target for controlling cell survival? Trends Pharmacol. Sci., 2006, doi:10.1016/j.tips.006.11.001.
8. Palazuelos, J.; Aguado, T.; Egia, A.; Mechoulam, R.; Guzman, M.; Galve-Roperh, I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J., 2006, 20 (13), 2405-2407.
9. Chao, C.C.; Hu, S.; Molitor, T.W.; Shaskan, E.G.; Peterson, P.K. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J. Immunol., 1992, 149 (8), 2736-2741.
10. Clarkson, A.N.; Rahman, R.; Appleton, I. Inflammation and auto-immunity as a central theme in neurodegenerative disorders: fact or fiction? Curr. Opin. Investig. Drugs., 2004, 5 (7), 706-713.
11. Bal-Price, A.; Brown, G.C. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J. Neurosci., 2001, 21 (17), 6480-6491.
12. Kowall, N.W.; Beal, M.F.; Busciglio, J.; Duffy, L.K.; Yankner, B.A. An in vivo model for the neurodegenerative effects of beta-amyloid and protection by substance-P. Proc. Natl. Acad. Sci. USA, 1991, 88 (16), 7247-7251.
13. Weldon, D.T.; Rogers, S.D.; Ghilardi, J.R.; Finke, M.P.; Cleary, J.P.; O'Hare, E.; Esler, W.P.; Maggio, J.E.; Mantyh, P.W. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J. Neurosci., 1998, 18 (6), 2161-2173.
14. Ramirez, B.G.; Blazquez, C.; del Pulgar, T.G.; Guzman, N.; de Ceballos, M.A.L. Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J. Neurosci., 2005, 25 (8), 1904-1913.
15. Streit, W.J. Microglia and neuroprotection: implications for Alzheimer's disease. Brain Res. Rev., 2005, 48 (2), 234-239. (Pubitemid 40585754)
16. Sapp, E.; Kegel, K. B.; Aronin, N.; Hashikawa, T.; Uchiyama, Y.; Tohyama, K.; Bhide, P.G.; Vonsattel, J.P.; DiFiglia, M. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol., 2001, 60 (2), 161-172.
17. Arai, H.; Furuya, T.; Mizuno, Y.; Mochizuki, H. Inflammation and infection in Parkinson's disease. Histol. Histopathol., 2006, 21 (6), 673-678.
18. Felts, P.A.; Woolston, A.M.; Fernando, H.B.; Asquith, S.; Gregson, N.A.; Mizzi, O.J.; Smith, K.J. Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide. Brain, 2005, 128 (Pt 7), 1649-1666.
19. Steiner, J.; Bielau, H.; Brisch, R.; Danos, P.; Ullrich, O.; Mawrin, C.; Bernstein, H. G.; Bogerts, B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res., 2008, 42 (2), 151-157. (Pubitemid 350061255)
20. Brown, D.R. Microglia and prion disease. Microsc. Res. Tech., 2001, 54 (2), 71-80.
21. Wierzba-Bobrowicz, T.; Lewandowska, E.; Schmidt-Sidor, B.; Gwiazda, E. The comparison of microglia maturation in CNS of normal human fetuses and fetuses with Down's syndrome. Folia Neuropathologica, 1999, 37 (4), 227-234.
22. Borlongan, C.V.; Yu, G.L.; Matsukawa, N.; Xu, L.; Hess, D.C.; Sanberg, P.R.; Wang, Y. Acute functional effects of cyclosporine- A and methylprednisolone treatment in adult rats exposed to transient ischemic stroke. Life Sci., 2005, 76 (13), 1503-1512. (Pubitemid 40164778)
23. Doutre, M.S. Ciclosporin. Ann. Dermatol. Venereol., 2002, 129 (4), 392-404.
24. Zhang, M.; Martin, B.R.; Adler, M.W.; Razdan, R.K.; Jallo, J.I.; Tuma, R.F. Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J. Cereb. Blood Flow Metab., 2007, 27 (7), 1387-1396.
25. Zhu, D.Y.; Liu, S.H.; Sun, H.S.; Lu, Y.M. Expression of inducible nitric oxide synthase after focal cerebral ischemia stimulates neurogenesis in the adult rodent dentate gyrus. J. Neurosci., 2003, 23 (1), 223-239.
26. Thored, P.; Wood, J.; Arvidsson, A.; Cammenga, J.; Kokaia, Z.; Lindvall, O. Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke. Stroke, 2007, 38 (11), 3032-3039. (Pubitemid 350035699)
27. Kim, S.H.; Won, S.J.; Mao, X.O.; Ledent, C.; Jin, K.L.; Greenberg, D.A. Role for neuronal nitric-oxide synthase in cannabinoid-induced neurogenesis. J. Pharmacol. Exp. Ther., 2006, 319 (1), 150-154.
28. Liu, B.; Hong, J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: Mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther., 2003, 304 (1), 1-7.
29. Chan, W.Y.; Kohsaka, S.; Rezaie, P. The origin and cell lineage of microglia - New concepts. Brain Res. Rev., 2007, 53 (2), 344-354. (Pubitemid 46177241)
30. Baker, D.; Jackson, S.J.; Pryce, G. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br. J. Pharmacol., 2007, 152 (5), 649-654. (Pubitemid 350034985)
31. Gehrmann, J.; Matsumoto, Y.; Kreutzberg, G.W. Microglia - Intrinsic immuneffector cell of the brain. Brain Res. Rev., 1995, 20 (3), 269-287.
32. Kreutzberg, G.W. Microglia: A sensor for pathological events in the CNS. Trends Neurosci., 1996, 19 (8), 312-318.
33. Melchior, B.; Puntambekar, S.S.; Carson, M.J. Microglia and the control of autoreactive T cell responses. Neurochem. Int., 2006, 49 (2), 145-153.
34. Nimmerjahn, A.; Kirchhoff, F.; Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science, 2005, 308 (5726), 1314-1318. (Pubitemid 40746128)
35. Buttini, M.; Boddeke, H. Peripheral lipopolysaccharide stimulation induces interleukin-1-Beta messenger-RNA in rat-brain microglial cells. Neuroscience, 1995, 65 (2), 523-530.
36. Gebicke-Haerter, P. J. Microglia in neurodegeneration: Molecular aspects. Microsc. Res. Tech., 2001, 54 (1), 47-58.
37. Stoll, G.; Jander, S.; Schroeter, M. Inflammation and glial responses in ischemic brain lesions. Prog. Neurobiol., 1998, 56 (2), 149-171.
38. Sun, D.M.; Hu, X.Z.; Liu, X.H.; Whitaker, J.N.; Walker, W.S. Expression of chemokine genes in rat glial cells: The effect of myelin basic protein-reactive encephalitogenic T cells. J. Neurosci. Res., 1997, 48 (3), 192-200.
39. Andersson, J.; Bjork, L.; Dinarello, C.A.; Towbin, H.; Andersson, U. Lipopolysaccharide induces human interleukin-1 receptor antagonist and interleukin-1 production in the same cell. Eur. J. Immunol., 1992, 22 (10), 2617-2623.
40. Mukhopadhyay, S.; Das, S.; Williams, E.A.; Moore, D.; Jones, J.D.; Zahm, D.S.; Ndengele, M.M.; Lechner, A.J.; Howlett, A.C. Lipopolysaccharide and cyclic AMP regulation of CB2 cannabinoid receptor levels in rat brain and mouse RAW 264.7 macrophages. J. Neuroimmunol., 2006, 181 (1-2), 82-92.
41. Dinarello, C.A. Inflammatory cytokines - Interleukin-1 and tumor-necrosis- factor as effector molecules in autoimmune-diseases. Curr. Opin. Immunol., 1991, 3 (6), 941-948.
42. Nikodemova, M.; Duncan, I.D.; Watters, J.J. Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and I kappa B alpha degradation in a stimulus-specific manner in microglia. J. Neurochem., 2006, 96 (2), 314-323.
43. Byram, S.C.; Carson, M.J.; DeBoy, C.A.; Serpe, C.J.; Sanders, V.M.; Jones, K.J. CD4-positive T cell-mediated neuroprotection requires dual compartment antigen presentation. J. Neurosci., 2004, 24 (18), 4333-4339.
44. Carlisle, S.J.; Marciano-Cabral, F.; Staab, A.; Ludwick, C.; Cabral, G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol., 2002, 2 (1), 69-82.
45. Carson, M.J. Microglia as liaisons between the immune and central nervous systems: Functional implications for multiple sclerosis. Glia, 2002, 40 (2), 218-231. (Pubitemid 35337379)
46. Walter, L.; Franklin, A.; Witting, A.; Wade, C.; Xie, Y.H.; Kunos, G.; Mackie, K.; Stella, N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci., 2003, 23 (4), 1398-1405. (Pubitemid 36258918)
47. Franklin, A.; Stella, N. Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol- sensitive receptors. Eur. J. Pharmacol., 2003, 474 (2-3), 195-198. (Pubitemid 37281448)
48. Miller, A.M.; Stella, N. CB2 receptor-mediated migration of immune cells: it can go either way. Br. J. Pharmacol., 2008, 153, 299-308.
49. Barron, K.D. The microglial cell. A historical review. J. Neurol. Sci., 1995, 134, 57-68.
50. Iadecola, C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci., 1997, 20 (3), 132-139. (Pubitemid 27086729)
51. Brown, G.C. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem. Soc. Trans., 2007, 35, 1119-1121.
52. Brown, G.C.; Cooper, C.E. Nanomolar concentrations of nitric-oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome-oxidase. FEBS Lett., 1994, 356 (2-3), 295-298.
53. Moncada, S.; Bolanos, J.P. Nitric oxide, cell bioenergetics and neurodegeneration. J. Neurochem., 2006, 97 (6), 1676-1689. (Pubitemid 43873660)
54. Endoh, M.; Maiese, K.; Wagner, J. Expression of the inducible form of nitric-oxide synthase by reactive astrocytes after transient global-ischemia. Brain Res., 1994, 651 (1-2), 92-100. (Pubitemid 24222853)
55. Ortega-Gutierrez, S.; Molina-Holgado, E.; Guaza, C. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia, 2005, 52 (2), 163-168. (Pubitemid 41652920)
56. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.D.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol., 2007, 39 (1), 44-84. (Pubitemid 44566469)
57. Familian, A.; Boshuizen, R.S.; Eikelenboom, P.; Veerhuis, R. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia, 2006, 53 (3), 233-240. (Pubitemid 43221345)
58. Veerhuis, R.; Van Breemen, M.J.; Hoozemans, J.J.M.; Morbin, M.; Ouladhadj, J.; Tagliavini, F.; Eikelenboom, P. Amyloid beta plaque-associated proteins C1q and SAP enhance the A beta(1-42) peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol., (Berl.), 2003, 105 (2), 135-144. (Pubitemid 36798799)
59. Eikelenboom, P.; Rozemuller, J.M.; Veerhuis, R. The role of microglia and a beta associated proteins in the pathogenesis of Alzheimer's disease. Glia, 2003, 41, 17-17
60. Cai, Z.; Lin, S.; Fan, L.W.; Pang, Y.; Rhodes, P.G. Minocycline alleviates hypoxic-ischemic injury to developing oligodendrocytes in the neonatal rat brain. Neuroscience, 2006, 137 (2), 425-435.
61. Macdonald, M.E.; Ambrose, C.M.; Duyao, M.P.; Myers, R.H.; Lin, C.; Srinidhi, L.; Barnes, G.; Taylor, S.A.; James, M.; Groot, N.; Macfarlane, H.; Jenkins, B.; Anderson, M.A.; Wexler, N.S.; Gusella, J.F.; Bates, G.P.; Baxendale, S.; Hummerich, H.; Kirby, S.; North, M.; Youngman, S.; Mott, R.; Zehetner, G.; Sedlacek, Z.; Poustka, A.; Frischauf, A.M.; Lehrach, H.; Buckler, A.J.; Church, D.; Doucettestamm, L.; Odonovan, M.C.; Ribaramirez, L.; Shah, M.; Stanton, V. P.; Strobel, S.A.; Draths, K.M.; Wales, J.L.; Dervan, P.; Housman, D.E.; Altherr, M.; Shiang, R.; Thompson, L.; Fielder, T.; Wasmuth, J.J.; Tagle, D.; Valdes, J.; Elmer, L.; Allard, M.; Castilla, L.; Swaroop, M.; Blanchard, K.; Collins, F.S.; Snell, R.; Holloway, T.; Gillespie, K.; Datson, N.; Shaw, D.; Harper, P.S. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtons-disease chromosomes. Cell, 1993, 72 (6), 971-983.
62. Ma, L.; Morton, A.J.; Nicholson, L.F. Microglia density decreases with age in a mouse model of Huntington's disease. Glia, 2003, 43 (3), 274-280.
63. Pavese, N.; Gerhard, A.; Tai, Y.F.; Ho, A.K.; Turkheimer, F.; Barker, R.A.; Brooks, D.J.; Piccini, P. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology, 2006, 66 (11), 1638-1643. (Pubitemid 43964614)
64. Pakkenberg, B.; Moller, A.; Gundersen, H.J.G.; Dam, A.M.; Pakkenberg, H. The absolute number of nerve-cells in substantia-nigra in normal subjects and in patients with Parkinsons-disease estimated with an unbiased stereological method. J. Neurol. Neurosurg. Psychiatr., 1991, 54 (1), 30-33.
65. Jenner, P.; Schapira, A.H.V.; Marsden, C.D. New insights into the cause of Parkinsons-disease. Neurology, 1992, 42 (12), 2241-2250.
66. Wu, D.C.; Jackson-Lewis, V.; Vila, M.; Tieu, K.; Teismann, P.; Vadseth, C.; Choi, D. K.; Ischiropoulos, H.; Przedborski, S. Blockade of microglial activation is neuroprotective in the 1-methyl-4- phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J. Neurosci., 2002, 22 (5), 1763-1771.
67. Yasuda, Y.; Shinagawa, R.; Yamada, M.; Mori, T.; Tateishi, N.; Fujita, S. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine. Brain Res., 2007, 1138, 196-202.
68. Imamura, K.; Hishikawa, N.; Sawada, M.; Nagatsu, T.; Yoshida, M.; Hashizume, Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. (Berl.), 2003, 106 (6), 518-526.
69. Mirza, B.; Hadberg, H.; Thomsen, P.; Moos, T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience, 2000, 95 (2), 425-432.
70. Fujinami, R.S.; Oldstone, M.B.A. Amino-acid homology between the encephalitogenic site of myelin basic-protein and virus - Mechanism for autoimmunity. Science, 1985, 230 (4729), 1043-1045.
71. Noseworthy, J.H. Progress in determining the causes and treatment of multiple sclerosis. Nature, 1999, 399 (6738), A40-A47.
72. Banati, R.B.; Newcombe, J.; Gunn, R.N.; Cagnin, A.; Turkheimer, F.; Heppner, F.; Price, G.; Wegner, F.; Giovannoni, G.; Miller, D.H.; Perkin, G.D.; Smith, T.; Hewson, A.K.; Bydder, G.; Kreutzberg, G.W.; Jones, T.; Cuzner, M.L.; Myers, R. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain, 2000, 123 (Pt 11) 2321-2337.
73. Zabad, R.K.; Metz, L.M.; Todoruk, T.R.; Zhang, Y.; Mitchell, J.R.; Yeung, M.; Patry, D.G.; Bell, R.B.; Yong, V.W. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult. Scler., 2007, 13 (4), 517-526.
74. Maier, K.; Merkler, D.; Gerber, J.; Taheri, N.; Kuhnert, A.V.; Williams, S.K.; Neusch, C.; Bahr, M.; Diem, R. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol. Dis., 2007, 25 (3), 514-525.
75. Walker, L.G.; Walker, M.B.; Heys, S.D.; Lolley, J.; Wesnes, K.; Eremin, O. The psychological and psychiatric effects of rIL-2 therapy: A controlled clinical trial. Psychooncology, 1997, 6 (4), 290-301.
76. Shanks, N.; Francis, D.; Zalcman, S.; Meaney, M.J.; Anisman, H. Alterations in central catecholamines associated with immune responding in adult and aged mice. Brain Res., 1994, 666 (1), 77-87.
77. Zalcman, S.; Greenjohnson, J.M.; Murray, L.; Nance, D.M.; Dyck, D.; Anisman, H.; Greenberg, A.H. Cytokine-specific central monoamine alterations induced Bp interleukin-1, interleukin-2 and interleukin- 6. Brain Res., 1994, 643 (1-2), 40-49.
78. Brown, D.R.; Schmidt, B.; Kretzschmar, H.A. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature, 1996, 380 (6572), 345-347.
79. Giese, A.; Brown, D.R.; Groschup, M.H.; Feldmann, C.; Haist, I.; Kretzschmar, H. A. Role of microglia in neuronal cell death in prion disease. Brain Pathol., (Zurich, Switzerland), 1998, 8 (3), 449-457.
80. Brown, D.R.; Schmidt, B.; Kretzschmar, H. A. A neurotoxic prion protein fragment enhances proliferation of microglia but not astrocytes in culture. Glia, 1996, 18 (1), 59-67.
81. Selvaggini, C.; Degioia, L.; Cantu, L.; Ghibaudi, E.; Diomede, L.; Passerini, F.; Forloni, G.; Bugiani, O.; Tagliavini, F.; Salmona, M. Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues-106-126 of the prion protein. Biochem. Biophys. Res. Commun., 1993, 194 (3), 1380-1386.
82. Wisniewski, H.M.; Wrzolek, M. Pathogenesis of amyloid formation in Alzheimer's-disease, downs-syndrome and scrapie. Ciba Found. Symp., 1988, 135, 224-238.
83. Nunez, E.; Benito, C.; Pazos, M.R.; Barbachano, A.; Fajardo, O.; Gonzalez, S.; Tolon, R.M.; Romero, J. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse (New York, N.Y.) 2004, 53 (4), 208-213.
84. Nunez, E.; Benito, C.; Tolon, R.M.; Hillard, C.J.; Griffin, W.S.T.; Romero, J. Glial expression of cannabinoid CB2 receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience, 2008, 151 (1), 104-110.
85. Goldgaber, D.; Harris, H.W.; Hla, T.; Maciag, T.; Donnelly, R.J.; Jacobsen, J.S.; Vitek, M.P.; Gajdusek, D.C. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA, 1989, 86 (19), 7606-7610.
86. Griffin, W.S.T.; Stanley, L.C.; Ling, C.; White, L.; Macleod, V.; Perrot, L.J.; White, C.L.; Araoz, C. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer-disease. Proc. Natl. Acad. Sci. USA, 1989, 86 (19), 7611-7615.
87. Joseph, R.; Tsang, W.; Han, E.; Saed, G.M. Neuronal beta-amyloid precursor protein gene-expression - regulation by aurintricarboxylic acid. Brain Res., 1993, 625 (2), 244-255.
88. Baigent, C.; Sudlow, C.; Collins, R.; Peto, R. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J., 2002, 324 (7329), 71-86.
89. Towfighi, J.; Yager, J.Y.; Housman, C.; Vannucci, R.C. Neuropathology of remote hypoxic-ischemic damage in the immature rat. Acta Neuropathol. (Berl.), 1991, 81 (5), 578-587.
90. Kabakus, N.; Ozcan, A.; Aysun, S.; Yilmaz, B. Evaluation of neuronal damage following hypoxic-ischaemic brain injury in acute and early chronic periods in neonatal rats. Cell Biochem. Funct., 2006, 24 (3), 257-260.
91. Andine, P.; Thordstein, M.; Kjellmer, I.; Nordborg, C.; Thiringer, K.; Wennberg, E.; Hagberg, H. Evaluation of brain-damage in a rat model of neonatal hypoxic-ischemia. J. Neurosci. Methods, 1990, 35 (3), 253-260.
92. Kaushal, V.; Schlichter, L.C. Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J. Neurosci., 2008, 28 (9), 2221-2230.
93. Clarkson, A.N.; Liu, H.Z.; Pearson, L.; Kapoor, M.; Harrison, J.C.; Sammut, I.A.; Jackson, D.M.; Appleton, I. Neuroprotective effects of spermine following hypoxia-ischemia-induced brain damage: A mechanistic study. FASEB J., 2004, 18 (7), 1114-1135.
94. Clarkson, A.N.; Liu, H.Z.; Rahman, R.; Jackson, D.M.; Appleton, I.; Kerr, D.S. Clomethiazole: mechanisms underlying lasting neuroprotection after hypoxia-ischemia. FASEB J., 2005, 19 (6), 1036-1060.
95. Sutherland, B.A.; Shaw, O.M.; Clarkson, A.N.; Jackson, D.M.; Sammut, I.A.; Appleton, I. Neuroprotective effects of (-)- epigallocatechin gallate after hypoxia-ischemia-induced brain damage: novel mechanisms of action. FASEB J., 2004, 18 (14), 258-280.
96. Fan, L.W.; Lin, S.; Pang, Y.; Rhodes, P.G.; Cai, Z. Minocycline attenuates hypoxia-ischemia-induced neurological dysfunction and brain injury in the juvenile rat. Eur. J. Neurosci., 2006, 24 (2), 341-350.
97. Lu, D.Y.; Liou, H.C.; Tang, C.H.; Fu, W.M. Hypoxia-induced iNOS expression in microglia is regulated by the P13- kinase/Akt/mTOR signaling pathway and activation of hypoxia inducible factor-1 alpha. Biochem. Pharmacol., 2006, 72 (8), 992-1000.
98. Sharp, F.R.; Bernaudin, M. HIf1 and oxygen sensing in the brain. Nat. Rev. Neurosci., 2004, 5 (6), 437-448.
99. Vannucci, R.C.; Connor, J.R.; Mauger, D.T.; Palmer, C.; Smith, M.B.; Towfighi, J.; Vannucci, S. J. Rat model of perinatal hypoxic-ischemic brain damage. J. Neurosci. Res., 1999, 55 (2), 158-163.
100. Bass, J.L.; Corwin, M.; Gozal, D.; Moore, C.; Nishida, H.; Parker, S.; Schonwald, A.; Wilker, R.E.; Stehle, S.; Kinane, T.B. The effect of chronic or intermittent hypoxia on cognition in childhood: A review of the evidence. Pediatrics, 2004, 114 (3), 805-816.
101. Klein, T.W.; Friedman, H.; Specter, S. Marijuana, immunity and infection. J. Neuroimmunol., 1998, 83 (1-2), 102-115.
102. Batkai, S.; Osei-Hyiaman, D.; Pan, H.; El-Assal, O.; Rajesh, M.; Mukhopadhyay, P.; Hong, F.; Harvey-White, J.; Jafri, A.; Hasko, G.; Huffman, J.W.; Gao, B.; Kunos, G.; Pacher, P. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J., 2007, 21 (8), 1788-1800.
103. Marchalant, Y.; Rosi, S.; Wenk, G.L. Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation. Neuroscience, 2007, 144 (4), 1516-1522.
104. Martinez-Orgado, J.; Fernandez-Frutos, B.; Gonzalez, R.; Romero, E.; Uriguen, L.; Romero, J.; Viveros, A.P. Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. Mol. Brain Res., 2003, 114 (2), 132-139.
105. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Lefur, G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 1995, 232 (1), 54-61.
106. Buckley, N.E.; McCoy, K.L.; Mezey, E.; Bonner, T.; Zimmer, A.; Felder, C.C.; Glass, M.; Zimmer, A. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol., 2000, 396 (2-3), 141-149.
107. Slipetz, D.M.; Oneill, G.P.; Favreau, L.; Dufresne, C.; Gallant, M.; Gareau, Y.; Guay, D.; Labelle, M.; Metters, K. M. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl-cyclase. Mol. Pharmacol., 1995, 48 (2), 352-361.
108. Bai, M.F.; Sexton, M.; Stella, N.; Bornhop, D.J. MBC94, a conjugable ligand for cannabinoid CB2 receptor imaging. Bioconjug. Chem., 2008, 19 (5), 988-992.
109. Ashton, J.C.; Friberg, D.; Darlington, C.L.; Smith, P.F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: An immunohistochemical study. Neurosci. Lett., 2006, 396 (2), 113-116.
110. Arevalo-Martin, A.; Garcia-Ovejero, D.; Gomez, O.; Rubio-Araiz, A.; Navarro-Galve, B.; Guaza, C.; Molina-Holgado, E.; Molina-Holgado, F. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. Br. J. Pharmacol., 2008, 153 (2), 216-225.
111. Cabral, G. A.; Raborn, E. S.; Griffin, L.; Dennis, J.; Marciano-Cabral, F. CB2 receptors in the brain: role in central immune function. Br. J. Pharmacol., 2008, 153, 240-251.
112. Dittel, B.N. Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor. Br. J. Pharmacol., 2008, 153 (2), 271-276.
113. Guindon, J.; Hohmann, A.G. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br. J. Pharmacol., 2008, 153, 319-334.
114. Hajrasouliha, A.R.; Tavakoli, S.; Ghasemi, M.; Jabehdar-Maralani, P.; Sadeghipour, H.; Ebrahimi, F.; Dehpour, A.R. Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart. Eur. J. Pharmacol., 2008, 579 (1-3), 246-252.
115. Maresz, K.; Carrier, E.J.; Ponomarev, E.D.; Hillard, C.J.; Dittel, B.N. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem., 2005, 95 (2), 437-445.
116. Zhang, M.; Martin, B.R.; Adler, M.W.; Razdan, R.K.; Jallo, J.I.; Tuma, R.F. Cannabinoid CB2 receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J. Cereb. Blood Flow Metab., 2007, 27 (7), 1387-1396.
117. Klegeris, A.; Bissonnette, C.; McGeer, P. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol., 2003, 139 (4), 775-786.
118. Fernandez-Lopez, D.; Martinez-Orgado, J.; Nunez, E.; Romero, J.; Lorenzo, P.; Moro, M. A.; Lizasoain, I. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr. Res., 2006, 60 (2), 169-173.
119. Alvarez-Buylla, A.; Garcia-Verdugo, J. M. Neurogenesis in adult subventricular zone. J. Neurosci., 2002, 22 (3), 629-634.
120. Gage, F.H. Neurogenesis in the adult brain. J. Neurosci., 2002, 22 (3), 612-613.
121. Zhao, C.M.; Deng, W.; Gage, F.H. Mechanisms and functional implications of adult neurogenesis. Cell, 2008, 132 (4), 645-660.
122. Noctor, S.C.; Flint, A.C.; Weissman, T.A.; Dammerman, R.S.; Kriegstein, A.R. Neurons derived from radial glial cells establish radial units in neocortex. Nature, 2001, 409 (6821), 714-720.
123. Liu, S.H.; Wang, J.; Zhu, D.Y.; Fu, Y.P.; Lukowiak, K.; Lu, Y.M. Generation of functional inhibitory neurons in the adult rat hippo-campus. J. Neurosci., 2003, 23 (3), 732-736.
124. Doetsch, F.; Caille, I.; Lim, D.A.; Garcia-Verdugo, J.M.; Alvarez-Buylla, A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell, 1999, 97 (6), 703-716.
125. Gould, E. Opinion - How widespread is adult neurogenesis in mammals? Nat. Rev. Neurosci., 2007, 8 (6), 481-488.
126. Doetsch, F.; Garcia Verdugo, J.M.; Alvarez Buylla, A. Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. J. Neurosci., 1997, 17 (13), 5046-5061.
127. Meshi, D.; Drew, M.R.; Saxe, M.; Ansorge, M.S.; David, D.; Santarelli, L.; Malapani, C.; Moore, H.; Hen, R. Hippocampal neurogenesis is not required for behavioral effects of environmental enrichment. Nat. Neurosci., 2006, 9 (6), 729-731.
128. Sisti, H.M.; Glass, A.L.; Shors, T.J. Neurogenesis and the spacing effect: learning over time enhances memory and the survival of new neurons. Learn. Mem., 2007, 14 (5), 368-375.
129. van Praag, H.; Christie, B.R.; Sejnowski, T.J.; Gage, F.H. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc. Natl. Acad. Sci. USA, 1999, 96 (23), 13427-13431.
130. Bruel-Jungerman, E.; Laroche, S.; Rampon, C. New neurons in the dentate gyrus are involved in the expression of enhanced long-term memory following environmental enrichment. Eur. J. Neurosci., 2005, 21 (2), 513-521.
131. Pourie, G.; Blaise, S.; Trabalon, M.; Nedelec, E.; Gueant, J.L.; Daval, J.L. Mild, non-lesioning transient hypoxia in the newborn rat induces delayed brain neurogenesis associated with improved memory scores. Neuroscience, 2006, 140 (4), 1369-1379.
132. Jin, K.L.; Peel, A.L.; Mao, X.O.; Xie, L.; Cottrell, B.A.; Henshall, D.C.; Greenberg, D.A. Increased hippocampal neurogenesis in Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2004, 101 (1), 343-347.
133. Seri, B.; Garcia-Verdugo, J. M.; McEwen, B.S.; Alvarez-Buylla, A. Astrocytes give rise to new neurons in the adult mammalian hippocampus. J. Neurosci., 2001, 21 (18), 7153-7160.
134. Lledo, P.M.; Saghatelyan, A. Integrating new neurons into the adult olfactory bulb: joining the network, life-death decisions, and the effects of sensory experience. Trends Neurosci., 2005, 28 (5), 248-254.
135. Alonso, M.; Viollet, C.; Gabellec, M.M.; Meas-Yedid, V.; Olivo-Marin, J.C.; Lledo, P.M. Olfactory discrimination learning increases the survival of adult-born neurons in the olfactory bulb. J. Neurosci., 2006, 26 (41), 10508-10513.
136. Gheusi, G.; Cremer, H.; McLean, H.; Chazal, G.; Vincent, J.D.; Lledo, P.M. Importance of newly generated neurons in the adult olfactory bulb for odor discrimination. Proc. Natl. Acad. Sci. USA, 2000, 97 (4), 1823-1828.
137. Gheusi, G.; Lledo, P.M. Importance of newly generated neurons in the adult olfactory bulb for odor discrimination. Med. Sci., 2000, 16 (4), 553-554.
138. Minger, S.L.; Ekonomou, A.; Carta, E.M.; Chinoy, A.; Perry, R.H.; Ballard, C.G. Endogenous neurogenesis in the human brain following cerebral infarction. Regen. Med., 2007, 2 (1), 69-74.
139. Daval, J.L.; Pourie, G.; Grojean, S.; Lievre, V.; Strazielle, C.; Blaise, S.; Vert, P. Neonatal hypoxia triggers transient apoptosis followed by neurogenesis in the rat CA1 hippocampus. Pediatr. Res., 2004, 55 (4), 561-567.
140. Vert, P.; Daval, J.L. Cell death and neurogenesis after hypoxia: a brain repair mechanism in the developing rat? Bull. Acad. Natl. Med., 2006, 190 (2), 469-481.
141. Belmadani, A.; Tran, P.B.; Ren, D.; Miller, R.J. Chemokines regulate the migration of neural progenitors to sites of neuroinflammation. J. Neurosci., 2006, 26 (12), 3182-3191.
142. Wang, Y.; Sheen, V.L.; Macklis, J.D. Cortical interneurons upregulate neurotrophins in vivo in response to targeted apoptotic degeneration of neighboring pyramidal neurons. Exp. Neurol., 1998, 154 (2), 389-402.
143. Jin, K.; Galvan, V.; Xie, L.; Mao, X.O.; Gorostiza, O.F.; Bredesen, D.E.; Greenberg, D.A. Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw,Ind) mice. Proc. Natl. Acad. Sci. USA, 2004, 101 (36), 13363-13367.
144. Curtis, M.A.; Penney, E.B.; Pearson, A.G.; van Roon-Mom, W.M.; Butterworth, N. J.; Dragunow, M.; Connor, B.; Faull, R.L. Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc. Natl. Acad. Sci. USA, 2003, 100 (15), 9023-9027.
145. Lie, D.C.; Song, H.J.; Colamarino, S.A.; Ming, G.L.; Gage, F.H. Neurogenesis in the adult brain: New strategies for central nervous system diseases. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 399-421.
146. Ekdahl, C.T.; Claasen, J.H.; Bonde, S.; Kokaia, Z.; Lindvall, O. Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl. Acad. Sci. USA, 2003, 100 (23), 13632-13637.
147. Monje, M.L.; Toda, H.; Palmer, T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science, 2003, 302 (5651), 1760-1765.
148. Carrier, E.; Kearn, C.; Barkmeier, A.; Breese, N.; Yang, W.; Nithipatikom, K.; Pfister, S.; Campbell, W.; Hillard, C. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptordependent mechanism. Mol. Pharmacol., 2004, 65 (4), 999-1007.
149. Eljaschewitsch, E.; Witting, A.; Mawrin, C.; Lee, T.; Schmidt, P.M.; Wolf, S.; Hoertnagl, H.; Raine, C.S.; Schneider-Stock, R.; Nitsch, R.; Ullrich, O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron, 2006, 49 (1), 67-79.
150. Kreutz, S.; Koch, M.; Ghadban, C.; Korf, H.W.; Dehghani, F. Cannabinoids and neuronal damage: Differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. Exp. Neurol., 2007, 203 (1), 246-257.
151. Cabral, G.A.; Marciano-Cabral, F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J. Leukoc. Biol., 2005, 78 (6), 1192-1197.
152. Pacher, P.; Hasko, G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br. J. Pharmacol., 2008, 153, 252-262.
153. Sun, Y.J.; Jin, K.L.; Childs, J.T.; Xie, L.; Mao, X.O.; Greenberg, D.A. Neuronal nitric oxide synthase and ischemia-induced neurogenesis. J. Cereb. Blood Flow Metab., 2005, 25 (4), 485-492.
154. Ziv, Y.; Schwartz, M. Immune-based regulation of adult neurogenesis: Implications for learning and memory. Brain Behav. Immun., 2008, 22 (2), 167-176.
155. Hess, D.C.; Borlongan, C.V. Stem cells and neurological diseases. Cell Prolif., 2008, 41, 94-114.
156. Fredriksson, R.; Lagerstrom, M.C.; Lundin, L.G.; Schioth, H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and finger-prints. Mol. Pharmacol., 2003, 63 (6), 1256-1272.
157. Lambert, D.M.; Fowler, C.J. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem., 2005, 48 (16), 5059-5087.
158. 2 adrenergenic G-protein- coupled receptor. Nature, 2007, 450 (7168), 383-387.
159. McAllister, S.D.; Rizvi, G.; Anavi-Goffer, S.; Hurst, D.P.; Barnett-Norris, J.; Lynch, D.L.; Reggio, P.H.; Abood, M.E. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/ inverse agonist binding region. J. Med. Chem., 2003, 46 (24), 5139-5152.
160. Montero, C.; Campillo, N.E.; Goya, P.; Paez, J.A. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study. Eur. J. Med. Chem., 2005, 40 (1), 75-83.
161. Ortega-Gutierrez, S.; Lopez-Rodriguez, M.L. CB1 and CB2 cannabinoid receptor binding studies based on modeling and mutagenesis approaches. Mini Rev. Med. Chem., 2005, 5 (7), 651-658.
162. Reggio, P.H. Cannabinoid receptors and their ligands: ligand-ligand and ligand-receptor modeling approaches. Handb. Exp. Pharmacol., 2005 (168), 247-281.
163. Reggio, P.H. Computational methods in drug design: modeling G protein-coupled receptor monomers, dimers, and oligomers. AAPS J., 2006, 8 (2), E322-336.
164. Salo, O.M.; Lahtela-Kakkonen, M.; Gynther, J.; Jarvinen, T.; Poso, A. Development of a 3D model for the human cannabinoid CB1 receptor. J. Med. Chem., 2004, 47 (12), 3048-3057.
165. Shim, J.Y.; Welsh, W.J.; Howlett, A.C. Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Biopolymers, 2003, 71 (2), 169-189.
166. Salo, O.M.; Raitio, K.H.; Savinainen, J.R.; Nevalainen, T.; Lahtela-Kakkonen, M.; Laitinen, J.T.; Jarvinen, T.; Poso, A. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. J. Med. Chem, 2005, 48 (23), 7166-7171.
167. Tuccinardi, T.; Ferrarini, P.L.; Manera, C.; Ortore, G.; Saccomanni, G.; Martinelli, A. Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis. J. Med. Chem, 2006, 49 (3), 984-994.
168. Xie, X.Q.; Chen, J.Z.; Billings, E.M. 3D structural model of the G-protein- coupled cannabinoid CB2 receptor. Proteins, 2003, 53 (2), 307-319.
169. Shim, J.Y.; Howlett, A.C. WIN55212-2 docking to the CB1 cannabinoid receptor and multiple pathways for conformational induction. J. Chem. Inf. Model., 2006, 46 (3), 1286-1300.
170. Raitio, K.H.; Salo, O.M.; Nevalainen, T.; Poso, A.; Jarvinen, T. Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands. Curr. Med. Chem., 2005, 12 (10), 1217-1237.
171. Makriyannis, A.; Rapaka, R.S. The molecular basis of cannabinoid activity. Life Sci., 1990, 47 (24), 2173-2184.
172. Aung, M.M.; Griffin, G.; Huffman, J.W.; Wu, M.; Keel, C.; Yang, B.; Showalter, V. M.; Abood, M.E.; Martin, B.R. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend., 2000, 60 (2), 133-140.
173. Reggio, P.H.; Basu-Dutt, S.; Barnett-Norris, J.; Castro, M.T.; Hurst, D.P.; Seltzman, H.H.; Roche, M.J.; Gilliam, A.F.; Thomas, B.F.; Stevenson, L.A.; Pertwee, R.G.; Abood, M.E. The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes. J. Med. Chem., 1998, 41 (26), 5177-5187.
174. McPartland, J.M.; Glass, M.; Pertwee, R.G. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br. J. Pharmacol., 2007, 152 (5), 583-593.
175. Tao, Q.; McAllister, S.D.; Andreassi, J.; Nowell, K.W.; Cabral, G.A.; Hurst, D.P.; Bachtel, K.; Ekman, M.C.; Reggio, P.H.; Abood, M.E. Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. Mol. Pharmacol., 1999, 55 (3), 605-613.
176. McAllister, S.D.; Hurst, D.P.; Barnett-Norris, J.; Lynch, D.; Reggio, P.H.; Abood, M. E. Structural mimicry in class A G proteincoupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J. Biol. Chem., 2004, 279 (46), 48024-48037.
177. Huffman, J.W.; Dai, D.; Martin, B.R.; Compton, D.R. Design, synthesis, and pharmacology of cannabimimetic indoles. Biomed. Chem., 1994, 4, 563-566.
178. McAllister, S.D.; Tao, Q.; Barnett-Norris, J.; Buehner, K.; Hurst, D.P.; Guarnieri, F.; Reggio, P.H.; Nowell, H.K.W.; Cabral, G.A.; Abood, M.E. A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. Biochem. Pharmacol., 2002, 63 (12), 2121-2136.
179. Raduner, S.; Majewska, A.; Chen, J.Z.; Xie, X.Q.; Hamon, J.; Faller, B.; Altmann, K.H.; Gertsch, J. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor- dependent and -independent immunomodulatory effects. J. Biol. Chem., 2006, 281 (20), 14192-14206.
180. Huffman, J.W. CB2 receptor ligands. Mini Rev. Med. Chem., 2005, 5 (7), 641-649.
181. Valenzano, K.J.; Tafesse, L.; Lee, G.; Harrison, J.E.; Boulet, J.M.; Gottshall, S. L.; Mark, L.; Pearson, M.S.; Miller, W.; Shan, S.; Rabadi, L.; Rotshteyn, Y.; Chaffer, S.M.; Turchin, P.I.; Elsemore, D.A.; Toth, M.; Koetzner, L.; Whiteside, G.T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology, 2005, 48 (5), 658-672.
182. Chin, C.N.; Murphy, J.W.; Huffman, J.W.; Kendall, D.A. The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J. Pharmacol. Exp. Ther., 1999, 291 (2), 837-844.
183. Malan, T.P., Jr.; Ibrahim, M.M.; Deng, H.; Liu, Q.; Mata, H.P.; Vanderah, T.; Porreca, F.; Makriyannis, A. CB2 cannabinoid receptor- mediated peripheral antinociception. Pain, 2001, 93 (3), 239-245.
184. Song, Z.H.; Slowey, C.A.; Hurst, D.P.; Reggio, P.H. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). Mol. Pharmacol., 1999, 56 (4), 834-840.
185. Hanus, L.; Breuer, A.; Tchilibon, S.; Shiloah, S.; Goldenberg, D.; Horowitz, M.; Pertwee, R.G.; Ross, R.A.; Mechoulam, R.; Fride, E. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. USA, 1999, 96 (25), 14228-14233.
186. Bissantz, C. Conformational changes of G protein-coupled receptors during their activation by agonist binding. J. Recept. Signal Transduct. Res., 2003, 23 (2-3), 123-153.
187. Kearn, C.S.; Greenberg, M.J.; DiCamelli, R.; Kurzawa, K.; Hillard, C.J. Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J. Neurochem., 1999, 72 (6), 2379-2387.
188. Picone, R.P.; Fournier, D.J.; Makriyannis, A. Ligand based structural studies of the CB1 cannabinoid receptor. J. Pept. Res., 2002, 60 (6), 348-356.
189. Gether, U.; Lin, S.; Ghanouni, P.; Ballesteros, J.A.; Weinstein, H.; Kobilka, B.K. Agonists induce conformational changes in trans-membrane domains III and VI of the beta2 adrenoceptor. EMBO J., 1997, 16 (22), 6737-16347
190. Ghanouni, P.; Gryczynski, Z.; Steenhuis, J.J.; Lee, T.W.; Farrens, D.L.; Lakowicz, J.R.; Kobilka, B.K. Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J. Biol. Chem., 2001, 276 (27), 24433-24436. (Pubitemid 37412900)
191. Jensen, A.D.; Guarnieri, F.; Rasmussen, S.G.; Asmar, F.; Ballesteros, J.A.; Gether, U. Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J. Biol. Chem., 2001, 276 (12), 9279-9290. (Pubitemid 37385512)
192. Ebersole, B.J.; Visiers, I.; Weinstein, H.; Sealfon, S.C. Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. Mol. Pharmacol., 2003, 63 (1), 36-43.
193. Wiley, J.L.; Compton, D.R.; Dai, D.; Lainton, J.A.; Phillips, M.; Huffman, J.W.; Martin, B.R. Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J. Pharmacol. Exp. Ther., 1998, 285 (3), 994-1004.
194. Huffman, J.W.; Lu, J.; Dai, D.; Kitaygorodskiy, A.; Wiley, J.L.; Martin, B.R. Synthesis and pharmacology of a hybrid cannabinoid. Bioorg. Med. Chem., 2000, 8 (2), 439-447.
195. Gallant, M.; Dufresne, C.; Gareau, Y.; Guay, D.; Leblanc, Y.; Prasit, P.; Rochette, C.; Sawyer, N.; Slipertz, D.M.; Tremblay, N.; Metters, K. M.; Labelle, M. New glass of potent rigands for the human peripheral cannabinoid receptor. Bioorg. Med. Chem. Lett., 1996, 6 (19), 2263-2268. (Pubitemid 26328497)
196. Yao, B.B.; Mukherjee, S.; Fan, Y.; Garrison, T.R.; Daza, A.V.; Grayson, G.K.; Hooker, B.A.; Dart, M.J.; Sullivan, J.P.; Meyer, M.D. In vitro pharmacologyical characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor. Br. J. Pharmacol., 2006, 149 145-154.
197. Pertwee, R.G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes., 2006, 30 (Suppl 1) S13-S18.
198. Makriyannis, A.; Deng, H. WO Patent 01/028557, 2001.
199. Huffman, J.W.; Padgett, L.W. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr. Med. Chem., 2005, 12 (12), 1395-1411.
200. Barth, F.; Millan, J.; Oustric, D.; Rinaldi, M.; Vernhet, M. WO Patent 01/032629 A1, 2001.
201. Page, D.; Walpole, C.; Yang, H. WO Patent 04/035548, 2004.
202. Gareau, Y.; Dufresne, C.; Gallant, M.; Rochette, C.; Sawyer, N.; Sipertz, D.M.; Tremblay, N.; Weech, P.K.; Metters, K.M.; Labelle, M. Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg. Med. Chem. Lett., 1996, 6, 189-194. (Pubitemid 26045675)
203. Huffman, J.W.; Liddle, J.; Yu, S.; Aung, M.M.; Abood, M.E.; Wiley, J.L.; Martin, B. R. 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8- THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem., 1999, 7 (12), 2905-2914.
204. Huffman, J.W.; Yu, S.; Showalter, V.; Abood, M.E.; Wiley, J.L.; Compton, D.R.; Martin, B.R.; Bramblett, R.D.; Reggio, P.H. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J. Med. Chem., 1996, 39 (20), 3875-3877.
205. Ross, R.A.; Brockie, H.C.; Stevenson, L.A.; Murphy, V.L.; Templeton, F.; Makriyannis, A.; Pertwee, R.G. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol., 1999, 126 (3), 665-672.
206. Huffman, J.W.; Bushell, S.M.; Miller, J.R.; Wiley, J.L.; Martin, B.R. 1-Methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1- methoxy-Delta(8)- tetrahydrocannabinols: new selective ligands for the CB2 receptor. Bioorg. Med. Chem., 2002, 10 (12), 4119-4129.
207. Adam, J.; Cowley, P.M.; Kiyoi, T.; Morrison, A.J.; Mort, C.J. Recent progress in cannabinoid research. Prog. Med. Chem., 2006, 44, 207-329.
208. Tada, Y.; Iso, Y.; Hanasaki, K. WO Patent 02/010135, 2002.
209. Manera, C.; Cascio, M.G.; Benetti, V.; Allara, M.; Tuccinardi, T.; Martinelli, A.; Saccomanni, G.; Vivoli, E.; Ghelardini, C.; Di Marzo, V.; Ferrarini, P.L. New 1,8-naphthyridine and quinoline derivatives as CB(2) selective agonists. Bioorg. Med. Chem. Lett., 2007, 17, 6505-6510.
210. Manera, C.; Benetti, V.; Castelli, M.P.; Cavallini, T.; Lazzarotti, S.; Pibiri, F.; Saccomanni, G.; Tuccinardi, T.; Vannacci, A.; Martinelli, A.; Ferrarini, P.L. Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin- 4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. J. Med. Chem., 2006, 49 (20), 5947-5957.
211. Fride, E.; Breuer, A.; Hanus, L.; Tchilibon, S.; Horowitz, M.; Mechoulam, R.; Garzon, A. US Patent 7214716, 2005.
212. Makriyannis, A.; Khanolkar, A. Peripheral cannabinoid receptor (CB2) selective ligands US Patent 323560 2006.
213. Khanolkar, A.; Lu, D.; Makriyannis, A. W.O. Patent 99/57107, 2001.
214. Kai, H.; Murashi, T.; Tomida, M. WO Patent 02/072562, 2002.
215. Hanasaki, K.; Murashi, T.; Kai, H. WO Patent 01/19807, 2001.
216. Gertsch, J.; Raduner, S.; Altmann, K.H. New natural noncannabinoid ligands for cannabinoid Type-2 (CB2) receptors. J. Recept. Signal. Transduct. Res., 2006, 26, 709-730.
217. Inaba, T.; Kaya, T.; Iwamura, H. WO Patent 97/29079, 1997.
218. Mussinu, J.M.; Ruiu, S.; Mule, A.C.; Pau, A.; Carai, M.A.; Loriga, G.; Murineddu, G.; Pinna, G. A. Trycyclic pyrazole, Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2- c]pyrazol-based ligands for CB1 and CB2 cannabinoid receptors. Bioorg. Med. Chem. Lett., 2003, 11 (2), 251-263.
219. Murineddu, G.; Lazzari, P.; Ruiu, S.; Sanna, A.; Loriga, G.; Manca, I.; Falzoi, M.; Dessi, C.; Curzu, M.M.; Chelucci, G.; Pani, L.; Pinna, G.A. Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2′,4′-Dichlorophenyl) -6-methyl-N-piperidin-1-yl-1,4-di- hydroindenol[1,2c]pyrazole-3-carboxamide. J. Med. Chem., 2007, 14 (59), 7502-7512.
220. Gonsiorek, W.; Lunn, C.A.; Fan, X.; Deno, G.; Kozlowski, J.; Hipkin, R.W. Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates. Br. J. Pharmacol., 2007, 151 (8), 1262-1271.
221. Friary, R.J.; Kozlowski, J.A.; Shankar, B.B.; Wong, M.K.C.; Zhou, G.; Lavey, B. J.; Shih, N.-Y.; Tong, L.; Chen, L.; Shu, Y. WO Patent 03/042174, 2003.
222. Tong, L.; Chem, L.; Shankar, B.B.; Kozlowski, J.; Shih, N.-Y. WO Patent 04/048322, 2004.
223. Kozlowski, J.; Shankar, B.B.; Shih, N.-Y.; Tong, L. WO Patent 04/000807, 2003.
224. Kozlowski, J.; Shih, N.-Y.; Lavey, B.J.; Rizvi, G.; Shankar, B.B.; Spitler, J.M.; Tong, L.; Wolin, R.L.; Wong, M.K.C. W.O. Patent 02/062750, 2002.